Teasing out Th1
EpiThany's strategy for creating more potent therapeutic cancer vaccines
EpiThany Inc. aims to increase the potency of therapeutic cancer vaccines by designing antigens that selectively activate immune-stimulating Th1 cells, without incurring the immunosuppressive effects caused by Th2 cell activation.
Like most cancer vaccines in development, EpiThany's deliver self-antigens -- pieces of proteins normally found in the body but produced at much higher levels in tumor cells than in healthy cells.
However, CEO Bill Watt told BioCentury the antigens EpiThany uses have been engineered to